MRKR

Marker Therapeutics Inc

Add to Watchlist

Advanced Chart

1.190

-0.04(-3.252%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

1.240

Open

1.240

VWAP

1.17

Vol

83.03K

Mkt Cap

13.46M

Low

1.165

Amount

97.45K

EV/EBITDA(TTM)

Total Shares

8.92M

-228.55K

EV/OCF(TTM)

P/S(TTM)

1.99

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. The Company’s multi antigen recognizing (MAR)-T cell technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens, which are tumor targets, and kill tumor cells expressing those targets. These T cells are designed to recognize multiple tumor targets to produce broad-spectrum anti-tumor activity. It is developing two product candidates, including an Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601) and an Off-the-Shelf (OTS) product in various indications (MT-401-OTS). It has developed MT-601 to recognize multiple target antigens expressed by the tumor, thereby limiting tumor adaptation by negative antigen selection or downregulation.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q1

FY2025Q2

0.00

-100%

723.00K

-38.16%

Estimates Revision

The market is revising No Change the revenue expectations for Marker Therapeutics, Inc. (MRKR) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 4.39%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Up

+4.39%

In Past 3 Month

1 Analyst Rating

572.27% Upside

Wall Street analysts forecast MRKR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MRKR is 8.00 USD with a low forecast of 8.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

572.27% Upside

Current: 1.190

Low

8.00

Averages

8.00

High

8.00

572.27% Upside

Current: 1.190

Low

8.00

Averages

8.00

High

8.00

WBB Securities

Steve Brozak

Strong Buy

Reiterates

$13

2025-04-01

Reason

WBB Securities

Steve Brozak

Price Target

$13

2025-04-01

Reiterates

Strong Buy

Reason

Canaccord Genuity

John Newman

Strong Buy

Initiates

2025-03-05

Reason

Canaccord Genuity

John Newman

Price Target

2025-03-05

Initiates

Strong Buy

Reason

Canaccord initiated coverage of Marker Therapeutics with a Buy rating and $8 price target.

Ladenburg Thalmann

Aydin Huseynov

Strong Buy

Maintains

$11 → $19

2024-10-21

Reason

Ladenburg Thalmann

Aydin Huseynov

Price Target

$11 → $19

2024-10-21

Maintains

Strong Buy

Reason

Ladenburg analyst Aydin Huseynov raised the firm's price target on Marker Therapeutics to $19 from $11 and keeps a Buy rating on the shares. Ladenburg is becoming more confident in seeing additional responses among post-CAR-T diffuse large B-cell lymphoma patients treated with neldaleucel by Q4, and tells investors in a research note that Marker's management appears focused on gathering a comprehensive dataset with sufficient statistical and clinical significance, which would support advancing to a pivotal Phase 2 trial with a single-arm and single-dose design for neldaleucel. The firm raised its probability of success for neldaleucel to 40% from 25% to 40% in post-CAR-T DLBCL based on the progress observed in this hard-to-treat population.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Marker Therapeutics Inc (MRKR.O) is -0.50, compared to its 5-year average forward P/E of -2.02. For a more detailed relative valuation and DCF analysis to assess Marker Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.02

Current PE

-0.50

Overvalued PE

-0.64

Undervalued PE

-3.41

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.01

Current EV/EBITDA

-0.02

Overvalued EV/EBITDA

0.12

Undervalued EV/EBITDA

-0.13

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

6.43

Current PS

5.37

Overvalued PS

16.98

Undervalued PS

-4.13

Financials

Annual

Quarterly

FY2025Q1

YoY :

-71.94%

349.10K

Total Revenue

FY2025Q1

YoY :

+63.03%

-4.16M

Operating Profit

FY2025Q1

YoY :

+85.81%

-4.45M

Net Income after Tax

FY2025Q1

YoY :

+48.15%

-0.40

EPS - Diluted

FY2025Q1

YoY :

-100.00%

N/A

Free Cash Flow

FY2025Q1

YoY :

0.00%

100.00

Gross Profit Margin - %

FY2025Q1

YoY :

+562.16%

-1.27K

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

1.8M

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

554.3K

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

1.8M

USD

Months

0-12

0.0

USD

Months

MRKR News & Events

Events Timeline

2025-06-17 (ET)

2025-06-17

08:05:15

Marker, Cellpoint announce collaboration for cGMP manufacturing of MT-601

2025-05-20 (ET)

2025-05-20

08:13:22

Marker Therapeutics reports evidence from Phase 1 APOLLO study

2025-03-31 (ET)

2025-03-31

08:49:15

Marker Therapeutics reports FY24 EPS ($1.19) vs ($1.59) last year

News

2.0

07-17Benzinga

Dow Jumps Over 100 Points; PepsiCo Posts Upbeat Earnings

7.5

06-17Newsfilter

Marker Therapeutics and Cellipont Bioservices Announce Collaboration to Advance cGMP Manufacturing of MT-601, a Multi-Antigen Recognizing T Cell Therapy for Patients with Lymphoma

9.0

05-20Newsfilter

Marker Therapeutics Reports that Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T Cells in Patients with Lymphoma